当前位置: 首页 >> 检索结果
2661. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure.
作者: L Gullestad.;H Aass.;J G Fjeld.;L Wikeby.;A K Andreassen.;H Ihlen.;S Simonsen.;J Kjekshus.;S Nitter-Hauge.;T Ueland.;E Lien.;S S Frøland.;P Aukrust.
来源: Circulation. 2001年103卷2期220-5页
Congestive heart failure (CHF) is characterized by enhanced immune activation, and immune-mediated mechanisms may play a pathogenic role in this disorder. Based on the immunomodulatory effects of intravenous immunoglobulin (IVIG), we hypothesized that IVIG could downregulate inflammatory responses in CHF patients and have potential beneficial effects on the left ventricular ejection fraction (LVEF).
2662. Effects of endothelin a receptor blockade on endothelial function in patients with chronic heart failure.
作者: R Berger.;B Stanek.;M Hülsmann.;B Frey.;S Heher.;R Pacher.;T Neunteufl.
来源: Circulation. 2001年103卷7期981-6页
Chronic heart failure (CHF) is associated with impaired endothelium-dependent vasodilation and increased basal vascular tone due, in part, to elevated endothelin-1 plasma levels. In the present study, we investigated whether a reduction of vascular tone using an endothelin A receptor blocker attenuates the impairment of endothelium-dependent, flow-mediated vasodilation (FMD).
2663. Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to IV congestive heart failure.
作者: G Torre-Amione.;J B Young.;J Durand.;B Bozkurt.;D L Mann.;I Kobrin.;C M Pratt.
来源: Circulation. 2001年103卷7期973-80页
Endothelin-1, a powerful mediator of vasoconstriction, is increased in patients with congestive heart failure and appears to be a prognostic marker that strongly is correlated with the severity of disease. However, little is known about the potential immediate beneficial effects of acute blockade of the endothelin system in patients with symptomatic left ventricular dysfunction. We assessed the hemodynamic effects and safety of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with moderate to severe heart failure.
2664. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization.
作者: M Crisby.;G Nordin-Fredriksson.;P K Shah.;J Yano.;J Zhu.;J Nilsson.
来源: Circulation. 2001年103卷7期926-33页
The clinical benefits of lipid lowering with statins are attributed to changes in plaque composition leading to lesion stability, but supporting clinical data from human studies are lacking. Therefore, we investigated the effect of 3 months of pravastatin treatment on composition of human carotid plaques removed during carotid endarterectomy.
2665. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE).
作者: E Lonn.;S Yusuf.;V Dzavik.;C Doris.;Q Yi.;S Smith.;A Moore-Cox.;J Bosch.;W Riley.;K Teo.; .
来源: Circulation. 2001年103卷7期919-25页
Activation of the renin-angiotensin-aldosterone system and oxidative modification of LDL cholesterol play important roles in atherosclerosis. The Study to Evaluate Carotid Ultrasound changes in patients treated with Ramipril and vitamin E (SECURE), a substudy of the Heart Outcomes Prevention Evaluation (HOPE) trial, was a prospective, double-blind, 3x2 factorial design trial that evaluated the effects of long-term treatment with the angiotensin-converting enzyme inhibitor ramipril and vitamin E on atherosclerosis progression in high-risk patients.
2666. Vitamin C augments the inotropic response to dobutamine in humans with normal left ventricular function.
We studied the effect of an antioxidant, the intracoronary infusion of vitamin C, on basal and dobutamine-stimulated left ventricular (LV) contractility.
2667. Effects of early use of atenolol or captopril on infarct size and ventricular volume: A double-blind comparison in patients with anterior acute myocardial infarction.
作者: J Galcerá-Tomás.;F J Castillo-Soria.;M M Villegas-García.;R Florenciano-Sánchez.;J G Sánchez-Villanueva.;J A de La Rosa.;A Martínez-Caballero.;J A Valentí-Aldeguer.;P Jara-Pérez.;M Párraga-Ramírez.;I López-Martínez.;L Iñigo-García.;F Picó-Aracil.
来源: Circulation. 2001年103卷6期813-9页
beta-Blockers and ACE inhibitors reduce early mortality when either one is started in the first hours after myocardial infarction (MI). Considering the close correlation between morphological changes and prognosis, we aimed to investigate whether the benefit of both beta-blockers and ACE inhibitors might reside in a similar protective effect on infarct size or ventricular volume.
2668. Comparative effect of ace inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase.
作者: B Hornig.;U Landmesser.;C Kohler.;D Ahlersmann.;S Spiekermann.;A Christoph.;H Tatge.;H Drexler.
来源: Circulation. 2001年103卷6期799-805页
Flow-dependent, endothelium-mediated vasodilation (FDD) and activity of extracellular superoxide dismutase (EC-SOD), the major antioxidative enzyme of the arterial wall, are severely impaired in patients with coronary artery disease (CAD). We hypothesized that both ACE inhibitor (ACEI) and angiotensin II type 1 receptor antagonist (AT(1)-A) increase bioavailability of nitric oxide (NO) by reducing oxidative stress in the vessel wall, possibly by increasing EC-SOD activity.
2669. Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment.
The common -514 C-->T polymorphism in the promoter region of the hepatic lipase (HL) gene affects HL activity. The C allele is associated with higher HL activity, more dense and atherogenic LDL, and lower HDL(2) cholesterol. Intensive lipid-lowering therapy lowers HL activity, increases LDL and HDL buoyancy, and promotes coronary artery disease (CAD) regression. We tested the hypothesis that subjects with the CC genotype and a more atherogenic lipid profile experience the greatest CAD regression from these favorable effects.
2670. Abnormal vascular reactivity in growth hormone deficiency.
作者: B Capaldo.;V Guardasole.;F Pardo.;M Matarazzo.;F Di Rella.;F Numis.;B Merola.;S Longobardi.;L Saccà.
来源: Circulation. 2001年103卷4期520-4页
The reason why patients with growth hormone (GH) deficiency (GHD) are at increased risk for premature cardiovascular death is still unclear. Although a variety of vascular risk factors have been identified in GHD, little is known regarding vascular reactivity and its contribution to premature arteriosclerosis.
2671. Intravenous immunoglobulin in acute rheumatic fever: a randomized controlled trial.
作者: L M Voss.;N J Wilson.;J M Neutze.;R M Whitlock.;R V Ameratunga.;L M Cairns.;D R Lennon.
来源: Circulation. 2001年103卷3期401-6页
Acute rheumatic fever (ARF) remains the leading cause of acquired heart disease in children worldwide. No therapeutic agent has been shown to alter the clinical outcome of the acute illness. Immunological mechanisms appear to be involved in the pathogenesis of ARF. Intravenous immunoglobulin (IVIG), a proven immunomodulator, may benefit cardiac conditions of an autoimmune nature. We investigated whether IVIG modified the natural history of ARF by reducing the extent and severity of carditis.
2672. Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project.
作者: R P Byington.;B R Davis.;J F Plehn.;H D White.;J Baker.;S M Cobbe.;J Shepherd.
来源: Circulation. 2001年103卷3期387-92页
Stroke is a leading cause of death and disability. Although clinical trials of the early lipid-lowering therapies did not demonstrate a reduction in the rates of stroke, data from recently completed statin trials strongly suggest benefit.
2673. Sex differences in the prognosis of congestive heart failure: results from the Cardiac Insufficiency Bisoprolol Study (CIBIS II).
Whether female sex is associated with a better prognosis in patients with congestive heart failure (CHF) remains uncertain. The Cardiac Insufficiency Bisoprolol Study (CIBIS) II showed that bisoprolol reduced all-cause mortality and morbidity rates in CHF patients treated with diuretics and ACE inhibitors. We examined whether survival was different in men (n=2132) and women (n=515) enrolled in CIBIS II.
2674. Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery.
作者: D L Bhatt.;D P Chew.;A T Hirsch.;P A Ringleb.;W Hacke.;E J Topol.
来源: Circulation. 2001年103卷3期363-8页
After coronary artery bypass surgery, patients have a high cumulative rate of graft closure and recurrent ischemic events. We sought to determine whether antiplatelet therapy with clopidogrel would be more effective than aspirin, the accepted standard, in these patients.
2675. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study.
作者: D J Freeman.;J Norrie.;N Sattar.;R D Neely.;S M Cobbe.;I Ford.;C Isles.;A R Lorimer.;P W Macfarlane.;J H McKillop.;C J Packard.;J Shepherd.;A Gaw.
来源: Circulation. 2001年103卷3期357-62页
We examined the development of new diabetes mellitus in men aged 45 to 64 years during the West of Scotland Coronary Prevention Study.
2676. Prognostic significance of thrombocytopenia during hirudin and heparin therapy in acute coronary syndrome without ST elevation: Organization to Assess Strategies for Ischemic Syndromes (OASIS-2)study.
作者: J W Eikelboom.;S S Anand.;S R Mehta.;J I Weitz.;C Yi.;S Yusuf.
来源: Circulation. 2001年103卷5期643-50页
The development of thrombocytopenia in acute coronary syndromes (ACS) appears to be associated with adverse clinical outcomes. Unfractionated heparin is a recognized cause of thrombocytopenia, but the incidence, predictors, and prognostic significance of thrombocytopenia during hirudin therapy in ACS have not been reported.
2677. Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen-progestin Replacement Study (HERS).
作者: J A Simon.;J Hsia.;J A Cauley.;C Richards.;F Harris.;J Fong.;E Barrett-Connor.;S B Hulley.
来源: Circulation. 2001年103卷5期638-42页
Observational studies have shown that postmenopausal hormone therapy may increase, decrease, or have no effect on the risk of stroke. To date, no clinical trial has examined this question. To investigate the relation between estrogen plus progestin therapy and risk of stroke among postmenopausal women, we analyzed data collected from the Heart & Estrogen-progestin Replacement Study (HERS), a secondary coronary heart disease prevention trial.
2678. Women's Healthy Lifestyle Project: A randomized clinical trial: results at 54 months.
作者: L H Kuller.;L R Simkin-Silverman.;R R Wing.;E N Meilahn.;D G Ives.
来源: Circulation. 2001年103卷1期32-7页
The Women's Healthy Lifestyle Project Clinical Trial tested the hypothesis that reducing saturated fat and cholesterol consumption and preventing weight gain by decreased caloric and fat intake and increased physical activity would prevent the rise in LDL cholesterol and weight gain in women during perimenopause to postmenopause.
2679. Local delivery of enoxaparin to decrease restenosis after stenting: results of initial multicenter trial: Polish-American Local Lovenox NIR Assessment study (The POLONIA study).
作者: R S Kiesz.;P Buszman.;J L Martin.;E Deutsch.;M M Rozek.;E Gaszewska.;M Rewicki.;P Seweryniak.;M Kosmider.;M Tendera.
来源: Circulation. 2001年103卷1期26-31页
Enoxaparin inhibits smooth muscle cell proliferation in experimental models. Intimal hyperplasia has been found to be the principal cause of restenosis after coronary stent implantation. We sought to determine whether the intramural delivery of enoxaparin before stenting of de novo lesions decreases restenosis.
2680. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti-factor Xa activity: A phase II evaluation. The Rembrandt Investigators.
来源: Circulation. 2000年102卷22期2726-31页
Patients with venous thromboembolism require initial treatment with an immediate-acting anticoagulant, low-molecular-weight heparin. We evaluated a novel synthetic factor Xa inhibitor (SR90107a/ORG31540) as an alternative treatment.
|